After participating
in this activity, participants should be able to:
 |
Assess the need for intravenous iron therapy to support erythropoiesis in selected patient populations
|
|
Identify and differentiate the IV iron products available in the US market today
|
|
Evaluate the published clinical data regarding the safety of IV iron infusion regimens
|
|
Identify the factors necessary to consider when establishing cost-effective guidelines for the use of IV iron therapy
|
Thomas Comstock,
PharmD
Associate Professor
Department of Pharmacy
Virginia Commonwealth University, School of Pharmacy
Richmond, VA |
|
|
ACCREDITATION / DESIGNATION
STATEMENT(S) : |
HDCN
is pleased to make available this web program devoted to the continuing
education of pharmacists.
 |
Pharmacy accreditation:
Medical Education Resources (MER) is approved by the American
Council of
Pharmaceutical Education as a provider of continuing pharmaceutical
education. MER designates this continuing education activity for 1.0
contact hours (0.10 CEUs) of the American Council on Pharmaceutical
Education. Expires December 30, 2005. Universal Program Number: #
816-000-03-020-H04.
|
Intended
Audience: Pharmacists. Note, this program is NOT intended
for physicians or nurses, and no physician CME or nursing CE credit
is available.
Needs
Statement: Studies and clinical experience have demonstrated
the important role for pharmacists in helping care for patients
with anemia. Staying abreast of developments in anemia therapy is
vital for the pharmacist to be able to optimize such care.
|
INSTRUCTIONS FOR PHARMACIST CE CREDIT : |
To earn Pharmacist CE credit for viewing the lectures, please
print and complete the CE Post test questions and return with
the completed Evaluation Form to Medical Education Resources,
Inc. via fax at (303) 798-5731 or mail at 1500 West Canal Court,
Suite 500, Littleton, Colorado 80120-5617.
|
CE credit for this program has expired.
|
| FACULTY
DISCLOSURE STATEMENTS : |
All faculty
participating in continuing medical education programs are expected
to disclose to the program audience any real or apparent conflict
of interest related to the subject under discussion. The faculty disclosure
information is as follows:
Thomas Comstock, PharmD is a consultant and speakers' bureau participant
for Watson Pharma, Inc.
|
DISCLOSURE OF UNLABELED USE (if applicable): |
This educational
activity contains discussion of published and/or investigational uses
of agents that are not indicated by FDA. Medical Education Resources,
Inc. or HDCN do not recommend the use of any agent outside of the
labeled indications. Please refer to the official prescribing information
for each product for discussion of approved indications, contraindications
and warnings.
All
of the agents overviewed in this virtual symposium will be discussed
in the context of uses for which they have not been approved by the
FDA. |
|
